Trial Profile

Oral Mucosal Escalation Goal Assessment (OMEGA) Study: A Randomized Placebo-Controlled Phase 1 Study of the Safety and Feasibility of Up-titration With INT301 in Adults With Sensitivity to Peanut

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Feb 2025 According to an Intrommune Therapeutics media release, results were published in the Annals of Allergy, Asthma & Immunology.
19 Feb 2025 Results presented in the Intrommune Therapeutics Media Release.
21 May 2024 According to an Intrommune Therapeutics media release, the company presented data at Citizens JMP Life Science Conference on 13th may 2024 and the BioNJ BioPartnering Conference on 14th May 2024 and the company CEO Michael Nelsonwill represent Intrommune as a panelist at the Annual Food Allergy Fund Summiton May 23rd, 2024 at 1:00pm EDT..

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com